JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Search

CareDx Inc

Cerrado

SectorSanidad

20.78 -0.38

Resumen

Variación precio

24h

Actual

Mínimo

20.23

Máximo

21.68

Métricas clave

By Trading Economics

Ingresos

-5.8M

-4.1M

Ventas

8.3M

108M

P/B

Media del Sector

14.645

67.147

BPA

0.12

Margen de beneficios

-3.79

Empleados

761

EBITDA

-5.7M

1.5M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+12.87% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

119M

1.1B

Apertura anterior

21.16

Cierre anterior

20.78

Noticias sobre sentimiento de mercado

By Acuity

65%

35%

183 / 348 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

CareDx Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

30 abr 2026, 23:08 UTC

Ganancias

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 abr 2026, 23:07 UTC

Ganancias

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 abr 2026, 22:20 UTC

Ganancias

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30 abr 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Rise After Gains on Wall Street -- Market Talk

30 abr 2026, 23:47 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

30 abr 2026, 23:47 UTC

Charlas de Mercado

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30 abr 2026, 23:27 UTC

Charlas de Mercado

Liontown Lithium Recovery Expected to Improve -- Market Talk

30 abr 2026, 23:22 UTC

Ganancias

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30 abr 2026, 23:20 UTC

Charlas de Mercado

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30 abr 2026, 22:52 UTC

Ganancias

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 abr 2026, 22:33 UTC

Ganancias

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30 abr 2026, 22:32 UTC

Ganancias

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30 abr 2026, 22:32 UTC

Ganancias

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30 abr 2026, 22:24 UTC

Adquisiciones, fusiones, absorciones

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30 abr 2026, 22:23 UTC

Adquisiciones, fusiones, absorciones

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30 abr 2026, 22:23 UTC

Adquisiciones, fusiones, absorciones

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30 abr 2026, 22:23 UTC

Adquisiciones, fusiones, absorciones

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30 abr 2026, 22:11 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

30 abr 2026, 22:11 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

30 abr 2026, 22:11 UTC

Charlas de Mercado

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30 abr 2026, 22:05 UTC

Ganancias

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30 abr 2026, 21:57 UTC

Ganancias

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30 abr 2026, 21:56 UTC

Ganancias

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30 abr 2026, 21:56 UTC

Ganancias

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30 abr 2026, 21:55 UTC

Ganancias

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30 abr 2026, 21:54 UTC

Ganancias

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30 abr 2026, 21:54 UTC

Ganancias

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30 abr 2026, 21:53 UTC

Ganancias

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30 abr 2026, 21:49 UTC

Ganancias

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30 abr 2026, 21:49 UTC

Ganancias

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Comparación entre iguales

Cambio de precio

CareDx Inc previsión

Precio Objetivo

By TipRanks

12.87% repunte

Estimación a 12 Meses

Media 24.73 USD  12.87%

Máximo 28 USD

Mínimo 21 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CareDx Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

6 ratings

2

Comprar

4

Mantener

0

Vender

Puntuación técnica

By Trading Central

14.77 / 18.49Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

183 / 348 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat